JP2017523189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523189A5 JP2017523189A5 JP2017505081A JP2017505081A JP2017523189A5 JP 2017523189 A5 JP2017523189 A5 JP 2017523189A5 JP 2017505081 A JP2017505081 A JP 2017505081A JP 2017505081 A JP2017505081 A JP 2017505081A JP 2017523189 A5 JP2017523189 A5 JP 2017523189A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- stage
- patent document
- dry powder
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 77
- 239000000843 powder Substances 0.000 claims description 40
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 33
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 16
- 238000012377 drug delivery Methods 0.000 claims description 13
- 230000000302 ischemic effect Effects 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 230000001052 transient effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 150000003904 phospholipids Chemical class 0.000 claims 8
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 7
- 239000008347 soybean phospholipid Substances 0.000 claims 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 6
- 230000000241 respiratory effect Effects 0.000 claims 6
- 208000005189 Embolism Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 8
- 208000006011 Stroke Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- JJBCTCGUOQYZHK-ZSCHJXSPSA-N 2-acetyloxybenzoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O JJBCTCGUOQYZHK-ZSCHJXSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000010906 Cyclooxygenase 1 Human genes 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462031811P | 2014-07-31 | 2014-07-31 | |
| US62/031,811 | 2014-07-31 | ||
| PCT/US2015/043128 WO2016019253A1 (en) | 2014-07-31 | 2015-07-31 | Dry powder formulations for inhalation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523189A JP2017523189A (ja) | 2017-08-17 |
| JP2017523189A5 true JP2017523189A5 (https=) | 2018-09-13 |
| JP6850524B2 JP6850524B2 (ja) | 2021-03-31 |
Family
ID=55218356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505081A Active JP6850524B2 (ja) | 2014-07-31 | 2015-07-31 | 吸入用の乾燥粉末製剤 |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP4218734A1 (https=) |
| JP (1) | JP6850524B2 (https=) |
| KR (2) | KR102603897B1 (https=) |
| CN (2) | CN116687887A (https=) |
| AU (2) | AU2015296142A1 (https=) |
| CA (1) | CA2991760C (https=) |
| DK (1) | DK3179986T3 (https=) |
| ES (1) | ES2942297T3 (https=) |
| PL (1) | PL3179986T3 (https=) |
| WO (1) | WO2016019253A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016176552A1 (en) * | 2015-04-30 | 2016-11-03 | Otitopic Inc. | Dry power formulations for inhalation |
| EP3463378A4 (en) * | 2016-06-03 | 2020-01-08 | Otitopic Inc. | DRY POWDER FORMULAS FOR INHALATION |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| JP7493449B2 (ja) * | 2017-09-22 | 2024-05-31 | ヴェクチュラ インコーポレイテッド | ステアリン酸マグネシウムを含む乾燥粉末組成物 |
| EP4311566A1 (en) | 2022-07-28 | 2024-01-31 | Vectura Inc. | An inhaler comprising a retention element |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| HU219899B (hu) | 1995-04-14 | 2001-09-28 | Glaxo Wellcome Inc. | Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban |
| ATE287703T1 (de) | 1995-04-14 | 2005-02-15 | Nektar Therapeutics | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| WO1998055104A1 (fr) * | 1997-06-06 | 1998-12-10 | Shionogi & Co., Ltd. | Perfectionnement d'un systeme d'administration de medicament |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| AU756693B2 (en) | 1997-09-29 | 2003-01-23 | Novartis Ag | Stabilized bioactive preparations and methods of use |
| GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| US7871598B1 (en) * | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| JP5698423B2 (ja) * | 2000-06-27 | 2015-04-08 | ベクトゥラ・リミテッド | 医薬組成物で使用するための粒子の製造法 |
| AU2002352836B2 (en) | 2001-11-20 | 2005-09-29 | Alkermes, Inc. | Improved particulate compositions for pulmonary delivery |
| GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
| US20040105821A1 (en) * | 2002-09-30 | 2004-06-03 | Howard Bernstein | Sustained release pharmaceutical formulation for inhalation |
| WO2005115341A2 (en) | 2004-05-27 | 2005-12-08 | Advanced Bionutrition Corporation | Microparticles for oral delivery |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| MX2007012045A (es) | 2005-03-28 | 2008-01-16 | Pericor Therapeutics Inc | Composiciones y formulaciones para evitar o reducir efectos adversos a un paciente. |
| MX2007015882A (es) * | 2005-06-13 | 2008-03-04 | Elan Pharma Int Ltd | Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina. |
| GB0621957D0 (en) | 2006-11-03 | 2006-12-13 | Vectura Group Plc | Inhaler devices and bespoke pharmaceutical compositions |
| US8614255B2 (en) | 2007-08-21 | 2013-12-24 | Civitas Therapeutics, Inc. | Pulmonary pharmaceutical formulations |
| AU2009214443B2 (en) | 2008-02-13 | 2013-10-10 | Board Of Regents, The University Of Texas System | Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| US20120160944A1 (en) | 2009-04-24 | 2012-06-28 | Aaron Dodd | Method for the production of commercial nanoparticle and micro particle powders |
| GB201102237D0 (en) * | 2011-02-09 | 2011-03-23 | Kuecept Ltd | Particle formulation |
| US9216527B2 (en) | 2012-02-09 | 2015-12-22 | G & W Electric Company | Solid-dielectric switch including a molded viewing window |
| NZ629438A (en) * | 2012-02-28 | 2016-10-28 | Iceutica Holdings Inc | Inhalable pharmaceutical compositions |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) * | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| AU2013388034B2 (en) * | 2013-04-30 | 2019-08-15 | Aspeya US Inc. | Dry powder formulations and methods of use |
| CN112656780A (zh) | 2014-02-20 | 2021-04-16 | 奥迪托皮克股份有限公司 | 用于吸入的干粉制剂 |
-
2015
- 2015-07-31 EP EP23154329.9A patent/EP4218734A1/en active Pending
- 2015-07-31 CN CN202310193558.5A patent/CN116687887A/zh active Pending
- 2015-07-31 KR KR1020177005617A patent/KR102603897B1/ko active Active
- 2015-07-31 WO PCT/US2015/043128 patent/WO2016019253A1/en not_active Ceased
- 2015-07-31 JP JP2017505081A patent/JP6850524B2/ja active Active
- 2015-07-31 AU AU2015296142A patent/AU2015296142A1/en not_active Abandoned
- 2015-07-31 DK DK15827152.8T patent/DK3179986T3/da active
- 2015-07-31 KR KR1020237026168A patent/KR102666667B1/ko active Active
- 2015-07-31 EP EP15827152.8A patent/EP3179986B1/en active Active
- 2015-07-31 CN CN201580052364.7A patent/CN107072947A/zh active Pending
- 2015-07-31 PL PL15827152.8T patent/PL3179986T3/pl unknown
- 2015-07-31 CA CA2991760A patent/CA2991760C/en active Active
- 2015-07-31 ES ES15827152T patent/ES2942297T3/es active Active
-
2020
- 2020-05-26 AU AU2020203437A patent/AU2020203437B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518388A5 (https=) | ||
| ES2664175T3 (es) | Formulación de polvo seco que comprende un inhibidor de fosfodiesterasa | |
| US10391078B2 (en) | Methods for the treatment of mast cell related disorders with mast cell stabilizers | |
| JP2017523189A5 (https=) | ||
| JP2022137070A5 (https=) | ||
| JP2014514271A (ja) | 頻拍を治療するためのグリコピロラートの使用 | |
| CN105377240A (zh) | 固体药物剂型 | |
| JP2007530620A (ja) | メロキシカムを含む組成物 | |
| JP5542309B2 (ja) | 経口医薬組成物 | |
| Al-Salama et al. | Glycopyrronium/formoterol: a review in COPD | |
| JP6850524B2 (ja) | 吸入用の乾燥粉末製剤 | |
| JP6415536B2 (ja) | ブデソニドおよびフォルモテロールを含む医薬組成物 | |
| Dhoble et al. | Site-specific delivery of inhalable antiangiogenic liposomal dry powder inhaler technology ameliorates experimental pulmonary hypertension | |
| JP5175710B2 (ja) | 急性および慢性気管支炎治療における吸入による非ステロイド系抗炎症剤の使用 | |
| ES2647223T3 (es) | Vapendavir para el alivio de los síntomas del asma en un sujeto que tiene una infección por el VRH | |
| JP5433295B2 (ja) | キサンタンガム被覆水溶性糖類及び圧縮成形製剤 | |
| CN110251473A (zh) | 羟哌吡酮口服缓释制剂 | |
| KR20230131179A (ko) | 폐 고혈압 분야를 위한 흡입형 이마티닙 | |
| KR102449403B1 (ko) | 부데소니드 및 포르모테롤을 함유하는 약학 조성물 | |
| JP6159128B2 (ja) | 抗ロタウイルス剤 | |
| JP7570499B2 (ja) | 肺炎を予防・治療する薬物におけるポリペプチドの応用 | |
| JP7119650B2 (ja) | 鎮痛剤 | |
| JP2013151565A (ja) | イブプロフェンの昇華が抑制された固形製剤 | |
| JP4318899B2 (ja) | 抗感冒剤 | |
| JPWO2005063253A1 (ja) | アレルギー症状治療用医薬組成物 |